MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 12, 2007; DOI: 10.1124/mol.106.031302


0026-895X/07/7106-1630-1639$20.00
Mol Pharmacol 71:1630-1639, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.031302v1
71/6/1630    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shadley, J. D.
Right arrow Articles by McCarver, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shadley, J. D.
Right arrow Articles by McCarver, D. G.

Identification and Functional Analysis of a Novel Human CYP2E1 Far Upstream Enhancer

Jeff D. Shadley, Karthika Divakaran, Kimber Munson, Ronald N. Hines, Kirk Douglas1, and D. Gail McCarver

Clinical Pharmacology, Pharmacogenetics & Teratology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

Both transcriptional and post-transcriptional CYP2E1 regulatory mechanisms are known, resulting in 20-fold or greater variation in CYP2E1 expression. To evaluate functional regulatory elements controlling transcription, CYP2E1 promoter constructs were used to make adenovirus vectors containing CYP2E1 promoter-driven luciferase reporters for analyses in both primary human hepatocytes and HepG2 cells. A 1.2-kilobase pair portion of the CYP2E1 promoter was associated with 5- to 10-fold greater luciferase activity. This upstream region contained five direct repeats of 59 base pairs (bp) that increased thymidine kinase-driven luciferase reporter activity in HepG2 cells more than 5-fold, regardless of orientation. Electrophoretic mobility shift assays (EMSAs) identified sequence-specific nuclear protein binding to the 59-bp repeats that was dependent on a 17-bp sequence containing a canonical GATA binding site (WGATAR). Competitive and supershift EMSA identified the participation of GATA4, another GATA family member or GATA-like factor, and a third factor unrelated to the GATA family. Involvement of the tricho-rhino-phalangeal syndrome-1 factor, which also binds a GATA sequence, was eliminated. Rather, competitive EMSA using known binding sequences for the orphan nuclear receptors, steroidogenic factor-1 (or NR5A1), and fetoprotein transcription factor (or NR5A2) implicated an NR5A member in binding a sequence overlapping the canonical GATA. Chromatin immunoprecipitation assay demonstrated in vivo binding of NR5A2 to the enhancer sequence in human hepatocytes. The enhancer sequence is conserved within the human population but seems species-specific. The identification of this novel enhancer and its putative mechanism adds to the complexities of human CYP2E1 regulation.


Received October 6, 2006; accepted March 9, 2007

Address correspondence to: Dr. Jeff D. Shadley, MFRC 5017, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI 53226-4801. E-mail: jshadley{at}mcw.edu




This article has been cited by other articles:


Home page
Plant CellHome page
M. Louwers, R. Bader, M. Haring, R. van Driel, W. de Laat, and M. Stam
Tissue- and Expression Level-Specific Chromatin Looping at Maize b1 Epialleles
PLANT CELL, March 1, 2009; 21(3): 832 - 842.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics